Prescribing Mirtazapine

Why Mirtazapine Matters

You reach for mirtazapine when its side effects are the treatment plan. Its efficacy for depression is real and, by meta-analysis, near the top of the class: Cipriani's network analyses repeatedly rank it among the more efficacious agents, alongside escitalopram, sertraline, venlafaxine, and amitriptyline. That edge is marginal, though, and it isn't why anyone prescribes the drug. People prescribe it because it makes patients sleep and eat, and because it rarely causes sexual dysfunction and rarely causes nausea, the two things patients hate most about SSRIs.

That's the whole pitch, and it's a good one. The depressed patient who can't fall asleep, has lost fifteen pounds, and lies awake with terminal insomnia is the patient mirtazapine was built for. Give it at bedtime and sleep and appetite improve within days, faster than the two-to-four-week antidepressant lag. It is one of the few antidepressants with a fast symptomatic payoff, because the sleep and appetite effects follow from histamine blockade, not from any slow neuroplastic remodeling.

The downside is just as simple, and it is why mirtazapine is a niche drug rather than a first-line one: it causes more weight gain than almost any other antidepressant, and its sedation can hurt as easily as it helps. Give it to a patient who is already overweight and sleeping twelve hours a day and you have made things worse, so choose the patient to fit the drug.

Mirtazapine is the lone widely used member of the NaSSA class (Noradrenergic and Specific Serotonergic Antidepressant). It often gets lumped with the "atypicals" (bupropion, trazodone, nefazodone, vortioxetine), but its mechanism is its own: it blocks receptors and does not inhibit reuptake, and that accounts for everything clinically distinctive about it.

Part 1: Indications

FDA-Approved Use

• Major depressive disorder (monotherapy)

That is the whole FDA label. Everything else is off-label, and the off-label uses are where the drug earns its keep.

Depression With Insomnia and Appetite Loss

This is the single best use of mirtazapine. The phenotype to look for:

• Depression with prominent insomnia, especially terminal insomnia / early-morning awakening, the sleep pattern typical of melancholia.
• Depression with anorexia, poor appetite, or unintentional weight loss (the underweight, not-eating patient).
• Depression with anxious distress, particularly in older or medically frail patients where SSRI activation is unwelcome.

When these features cluster (the classic underweight, non-sleeping, anxious depressed patient), mirtazapine is often the right first choice, not a fallback. Its sleep-architecture benefit is objective: polysomnography data show it increases deep stage N3 slow-wave sleep and reduces nighttime awakenings (Karsten et al., 2017), which is more than you can say for trazodone at the low doses people actually use.

Other Off-Label Uses

Antipsychotic-induced akathisia. This is a useful and underused indication. At least two RCTs and a 2024 network meta-analysis (Gerolymos et al., JAMA Netw Open) found low-dose mirtazapine (15 mg) among the most effective agents for antipsychotic-induced akathisia, arguably better than propranolol, which that analysis suggested is weaker than we'd assumed. The randomized trials used 15 mg once daily, so that is the dose to use for this indication. (Vitamin B6 / pyridoxine has a better tolerability-to-efficacy ratio and is a reasonable co-first-line for akathisia.)

SSRI-induced sexual dysfunction (add-on). Mirtazapine 15–45 mg at night can restore orgasm in patients anorgasmic on an SSRI, by blocking the postsynaptic 5-HT2A receptors whose stimulation drives the dysfunction. Evidence is open-label only, but the mechanism is sound and the risk is low.

SSRI-induced excessive sweating and SSRI-induced nausea. The same 5-HT2/5-HT3 blockade that keeps mirtazapine itself nausea-free can blunt these SSRI side effects when a low dose is added.

Comorbid anxiety in depression. Reasonable evidence for depression with anxious distress; no clear superiority over other agents, but the sedation helps.

Uses That Sound Good But Aren't

The mirtazapine literature has plenty of attractive theories that large, well-designed trials have since flattened. Don't fall for them.

Augmentation of a partially responsive antidepressant in treatment-resistant depression. This is the big one. "California Rocket Fuel" (venlafaxine plus mirtazapine) was oversold on the theory that adding a noradrenergic/serotonergic antagonist to an SNRI would be synergistic. The rigorous trials are negative:

• Kessler et al. (BMJ 2018, n=480): mirtazapine added to an SSRI/SNRI in primary-care non-responders gave 29% remission vs. 24% placebo (p=0.09), failed to separate, and the trivial advantage faded over the next nine months.
• CO-MED (Rush et al., 2011): venlafaxine plus mirtazapine gave 38% remission vs. escitalopram monotherapy 39%, no advantage to the combination whatsoever.
• Navarro et al. (2019): in venlafaxine non-responders, mirtazapine augmentation gave 39% remission while switching to imipramine gave 71%; switching nearly doubled the remission rate.
• Henssler meta-analysis (JAMA Psychiatry 2022): a modest pooled SMD of ~0.37, but nearly all the large mirtazapine-combination RCTs were negative.

For a patient who has partially responded to an SSRI/SNRI, switching, or augmenting with something that has real evidence (an atypical antipsychotic, lithium, T3), beats adding mirtazapine. The one legitimate exception is the patient who also has insomnia and weight loss, where you're adding mirtazapine for those symptoms, not for a synergistic antidepressant effect.

Combat-related PTSD monotherapy. The mechanistic story is appealing (dampening noradrenergic arousal, improving sleep), but the Davis et al. trial (2020, n=78 veterans, mean 39 mg/day) failed its primary PTSD outcome and, surprisingly for a sedating drug, did not improve sleep and appeared to increase nightmares. Mirtazapine may still help SSRI-treated PTSD patients with residual sleep disruption, but do not use it as PTSD monotherapy.

OCD. Do not expect mirtazapine to treat OCD, and be cautious: as a potent 5-HT2A antagonist, it can theoretically provoke or worsen obsessive-compulsive symptoms. (There is one small positive augmentation-to-sertraline trial, but the signal is weak and the mechanistic concern is real.)

First-line in high-neuroticism patients. In head-to-head data, high-neuroticism patients did worse on mirtazapine (36% remission at 8 weeks) than on an SSRI (74%). If the patient's temperament is anxious-ruminative rather than melancholic-insomniac, an SSRI is the better bet.

Part 2: Before You Start: Workup and Candidacy

Mirtazapine requires very little workup. There is no therapeutic level to chase, no narrow window, no mandatory baseline panel.

Before Starting

No CBC is required at baseline, despite the agranulocytosis language in the label (see Part 6), and no routine ECG is required either. There are no serum drug levels to monitor; this is not a tricyclic.

The Ideal Candidate

• Depressed and not sleeping and not eating.
• Underweight, or at least not weight-preoccupied.
• Bothered by (or unwilling to risk) SSRI sexual dysfunction: mirtazapine is a favorite in correctional and male-heavy populations for exactly this reason.
• Prone to SSRI/SNRI nausea.
• Elderly with insomnia and poor appetite (a classic geriatric fit, with fall-risk caveats below).

The Poor Candidate

• Overweight or weight-preoccupied patients, or anyone with metabolic syndrome you're trying not to worsen.
• Patients who are already hypersomnic or who need to be alert and functional during the day.
• High-neuroticism, anxious-ruminative depression without prominent insomnia (an SSRI is better).
• A bipolar patient without a mood stabilizer.

Part 3: How to Start and Dose

Formulations

Mirtazapine comes as standard oral tablets and an orally disintegrating tablet (ODT, "SolTab") in 15, 30, and 45 mg. The standard tablet also comes in a 7.5 mg strength. The ODT is convenient for patients who won't reliably swallow a pill, but it is not absorbed sublingually: it dissolves and is swallowed, so the pharmacokinetics are the same as the tablet.

Dose and Sedation

The most repeated teaching about mirtazapine dosing does not hold up:

The reasoning is that H1 antihistamine blockade dominates at low doses and that rising noradrenergic tone, from alpha-2 autoreceptor blockade releasing norepinephrine, offsets it as the dose climbs. Tertiary references repeat it. The FDA asked for a post-marketing study of the relationship between dose and sedation when it approved the drug, and none has been completed; a 2021 review that asked the manufacturer for supporting data was sent a case report, a retrospective review and a pharmacokinetic analysis, none of which addressed the question. Receptor imaging runs the other way: a 15 mg dose already occupies 80 to 90% of cortical histamine H1 receptors, and occupancy tracked plasma concentration and subjective sleepiness. A systematic review of the sedation literature concluded that raising the dose does not reliably reduce sedation within the usual range.

So treat sedation as a property of the drug rather than of the dose. Somnolence was reported by 54% of patients in the registration trials against 18% on placebo, and the label says it is unclear whether tolerance develops. If a patient is too groggy, move the dose earlier in the evening, lower it, or change drugs. Raising it to bring in an offset that has never been demonstrated is not a plan.

Starting Dose and Titration

• Start: 15 mg at bedtime (some clinicians start 7.5 mg; 15 mg once daily in the evening is the label's starting dose).
• Titrate by 15 mg every 1–2 weeks as needed for antidepressant effect, guided by response and tolerability.
• Therapeutic range: 15–45 mg/day, all at bedtime.
• Maximum: 45 mg/day.

The Dose-Response Ceiling: Don't Chase 45 mg

The efficacy data (Furukawa meta-analysis, Lancet Psychiatry 2019) are clear and clinically useful: antidepressant efficacy increases up to about 30 mg/day and then plateaus or even declines above 30 mg, while adverse-effect dropouts rise sharply.

The practical target for depression is 15–30 mg. Going to 45 mg buys little extra antidepressant benefit and costs tolerability. Reserve 45 mg for patients who have clearly tolerated 30 mg and plausibly need more; it shouldn't be a routine destination.

Dose by the Goal

Timing

Dose at bedtime, always. If daytime grogginess (a "hangover") is a problem, moving the dose to early evening can help by shifting the peak earlier.

Onset

Unlike the classic two-to-four-week antidepressant lag, the sleep and appetite effects appear within days. The full mood effect still takes the usual 4–8 weeks; reassess response at that point. Meta-analyses credit mirtazapine with a somewhat faster onset of antidepressant action than citalopram, fluoxetine, paroxetine, or sertraline.

Dose Adjustments and Special Populations

• Hepatic impairment: clearance falls roughly 30%; start low and titrate cautiously.
• Renal impairment: clearance is reduced (~30% in moderate, ~50% in severe impairment or ESRD); use lower doses and monitor.
• Geriatric: reduced clearance and a real fall risk from sedation; start 7.5–15 mg and go slow.
• Pediatric: not FDA-approved (pediatric MDD trials were negative).

Stopping and Switching

• Discontinuation: taper to avoid discontinuation symptoms (dizziness, nausea, anxiety, insomnia); rebound insomnia and appetite changes can occur after abrupt stops.
• MAOI washout: allow 14 days in each direction between mirtazapine and an MAOI.

Part 4: Monitoring

Mirtazapine's monitoring burden is minimal, the opposite of lithium: no levels, no mandatory labs, and no ECG requirement.

If there's no meaningful response by 4–8 weeks at an adequate dose (15–30 mg), switch agents rather than push higher or augment.

Part 5: Side Effects and How to Manage Them

Mirtazapine's side effects are dominated by sedation and weight gain, both driven by H1 antihistamine blockade, and nearly everything else about its tolerability is a plus. The skill in managing it is deciding whether the sedation and appetite help or hurt your particular patient.

Weight Gain and Increased Appetite: the Defining Liability

Weight gain is the reason mirtazapine isn't first-line for most depression. By reputation and by data it is among the worst antidepressants for weight gain; one Carlat expert put it bluntly, "probably the worst." Reported figures vary widely across a noisy literature (some sources cite very high proportions gaining clinically significant weight), but a large share of patients gain weight, often on the order of several kilograms over months, and it is frequently the reason they quit. Carbohydrate craving is a specific and common complaint.

• Mechanism: H1 antagonism (with a contribution from 5-HT2C blockade) drives appetite.
• Set expectations up front: tell every patient this will likely increase appetite and may add weight, and that you'll be tracking it.
• Dietary and exercise counseling from day one, not after ten pounds are on.
• Lower doses may attenuate it, though the appetite effect is present even at low doses.
• Monitor weight every visit.
• If weight gain is intolerable, switch: to bupropion (weight-neutral to weight-reducing), or to trazodone/nefazodone if you need a sedating agent with less weight liability.

Sedation and Drowsiness

• Common at every dose in the range: somnolence was reported by 54% of patients in the registration trials against 18% on placebo.
• Dose at bedtime: make the sedation work for you.
• If daytime grogginess persists, move the dose earlier in the evening.
• Consider a lower dose (7.5 mg) if sedation is excessive and you only need the sleep/appetite effect.
• As a last resort for otherwise-good responders, an activating agent (a stimulant or modafinil-class drug) can be layered, but reconsider the drug choice first.
• In the elderly, sedation translates directly into fall risk (see Special Populations).

Sexual Function

Mirtazapine has low rates of sexual dysfunction, one of the best profiles in the class, because it lacks the serotonin-reuptake blockade that drives SSRI/SNRI dysfunction and because its 5-HT2A/5-HT2C antagonism actively counteracts it. This is a primary reason to choose it, and a reason it's used to rescue SSRI-induced dysfunction.

GI

Mirtazapine is, for practical purposes, nausea-neutral. In a 15-antidepressant meta-analysis (Oliva et al., 2021), it was the only agent not associated with nausea/vomiting, courtesy of H1 antagonism plus 5-HT3 blockade (the same mechanism ondansetron uses). It is also not a diarrhea offender. If a patient can't tolerate SSRI/SNRI GI effects, this is a natural landing spot.

Anticholinergic Effects (Mild)

Mild dry mouth and constipation can occur.

• Dry mouth: sugar-free gum/lozenges, saliva substitutes; bethanechol 25 mg BID in stubborn cases.
• Constipation: fiber, fluids, docusate, polyethylene glycol; avoid chronic stimulant laxatives.

Orthostatic Hypotension / Dizziness

Possible, especially on standing quickly and especially in the elderly. Bedtime dosing helps; counsel slow position changes; monitor in older patients.

Vivid Dreams / Nightmares

Can occur, and were prominent (and problematic) in the PTSD trial data. If distressing, this is a reason to reconsider the drug in that patient.

Rare Effects

• Elevated lipids / glucose dysregulation: monitor in metabolically vulnerable patients.
• Mania/hypomania induction in bipolar-spectrum patients.
• Agranulocytosis (see Part 6; extremely rare).

Part 6: Overdose, Toxicity, and Boxed Warnings

Overdose

Mirtazapine is one of the safer antidepressants in overdose and markedly safer than tricyclics, a real advantage, especially in a population with suicide risk. Overdose typically produces sedation, tachycardia, and mild disorientation; it is not associated with the lethal cardiac conduction toxicity of TCAs and is not a significant lethal-overdose agent on its own. Management is supportive care. As always, danger rises with co-ingestants (alcohol, benzodiazepines, opioids, additive CNS depression).

The Boxed Warnings

Agranulocytosis is also a labeled serious warning. Premarketing trials recorded a small number of cases. In practice it is extremely rare and unpredictable and does not warrant routine CBC monitoring; the prescribing information does not recommend scheduled blood counts. Check a CBC only if the patient develops signs of infection (fever, sore throat, stomatitis, or other flu-like illness), and discontinue if agranulocytosis is confirmed.

QTc

Mirtazapine appears on lists of QTc-prolonging drugs, but the real-world signal is small. In a hospital study of adding a second QTc-active drug, only ~2% developed a prolonged QTc and there were no cases of torsades or sudden death. No routine ECG is required; use ordinary caution when stacking multiple QTc-active agents or in patients with baseline prolongation.

Seizure

Mirtazapine sits in the middle-to-low range for seizure risk, lower than clomipramine, amitriptyline, venlafaxine, and several SSRIs, though higher than escitalopram and fluoxetine. It is not contraindicated in seizure history and carries no bupropion-like seizure warning.

Part 7: Drug Interactions

Mirtazapine's interaction profile is clean, which counts for a lot in polypharmacy and in the medically complex or elderly patient.

Pharmacokinetic Interactions: Minimal

• Metabolized by CYP2D6, CYP3A4, and CYP1A2, but it is not a meaningful inhibitor or inducer of these enzymes. It does not raise the levels of other drugs the way fluoxetine, paroxetine, or fluvoxamine can.
• Strong CYP3A4/2D6 inhibitors or inducers can modestly shift mirtazapine levels, but this rarely requires action given the wide safety margin.
• With warfarin: monitor INR; a minor interaction is possible.

Pharmacodynamic Interactions

• CNS depressants (alcohol, benzodiazepines, opioids, antihistamines, Z-drugs): additive sedation. This is the practically important interaction: counsel patients, and take special care in the elderly and in those on opioids.
• MAOIs: contraindicated within 14 days (serotonin-syndrome risk). Some experts consider mirtazapine one of the safer agents to combine with an MAOI when this is done deliberately and under close supervision, but standard practice is to observe the 14-day washout.
• Other serotonergic agents (SSRIs/SNRIs): additive serotonergic effect is theoretically possible but not clinically significant in practice; serotonin syndrome from mirtazapine combinations is rare.
• No tyramine interaction (unlike MAOIs).
• Low bleeding risk: unlike SSRIs/SNRIs, mirtazapine does not meaningfully impair platelet aggregation, an advantage in patients on anticoagulants/antiplatelets or NSAIDs.

Part 8: Special Populations

Pregnancy

Data are limited. Historically FDA Pregnancy Category C; no consistent signal of major teratogenicity has emerged, but the evidence base is thin. Some clinicians reach for it in pregnancy specifically when a depressed patient also has nausea/hyperemesis and poor intake with insomnia, for its antiemetic and appetite effects. Individualize the decision, weighing the substantial risk of untreated maternal depression; coordinate with obstetrics.

Lactation

Mirtazapine passes into breast milk in low amounts; infant exposure is generally low but data are limited. Discuss risks and benefits; if used, watch the infant for sedation and poor feeding. Better-characterized agents (e.g., sertraline) are often preferred if the clinical picture allows.

Elderly

Mirtazapine is a strong option in late-life depression with insomnia and poor appetite/weight loss, a common and hard-to-treat geriatric presentation where SSRIs may worsen appetite and sleep.

• Start low, go slow: 7.5–15 mg QHS; titrate by 7.5–15 mg every 1–2 weeks.
• Target 15–30 mg; the full 45 mg is rarely needed.
• Watch closely for: falls (sedation plus orthostasis), cognitive dulling from oversedation, and hyponatremia (SIADH, a class effect of antidepressants in the elderly).
• Advantages here: no sexual-dysfunction concern, fixes appetite and sleep, and a low interaction burden in the polypharmacy patient.

Hepatic Impairment

Mirtazapine is hepatically metabolized; clearance is reduced in hepatic impairment. Reduce the dose and titrate cautiously, watching for exaggerated sedation.

Renal Impairment

Clearance is also reduced in renal impairment. The label calls for a dose decrease in moderate to severe renal impairment, so use lower doses and monitor.

Children and Adolescents

Limited data; not FDA-approved for pediatric depression (only fluoxetine and escitalopram are). Use is off-label and non-standard, reserved for select cases (e.g., depression with severe insomnia) after first-line SSRIs. If used, start 7.5 mg and titrate carefully. The pediatric suicidality boxed warning applies with full force.

Bipolar Disorder

Can precipitate mania/hypomania like any antidepressant. Do not use as monotherapy in bipolar depression: pair it with a mood stabilizer or choose a different strategy.

Part 9: Discontinuation

Mirtazapine carries a labeled discontinuation syndrome, so taper it.

• The label lists discontinuation reactions, particularly after abrupt stops: dizziness, abnormal dreams, sensory disturbances including paresthesia and electric shock sensations, agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting and sweating.
• The ~20–40 hour half-life is long enough for once-daily dosing and too short to taper the drug for you.
• A gradual taper over 1–2 weeks is reasonable for comfort and to watch for relapse. The label recommends reducing the dose gradually rather than stopping abruptly.

As with all antidepressants, discontinuation of successful treatment still risks relapse of the underlying depression: a maintenance trial found higher relapse on discontinuation (~56%) than on continuation (~39%) over a year. A taper protects against withdrawal but not against recurrence; how long to maintain treatment is a separate clinical decision.

Part 10: Mirtazapine vs the Alternatives

Efficacy across modern antidepressants is broadly similar (~60% response), so you choose on side effects and target symptoms:

Where mirtazapine is unique or best: the fast fix for depression with insomnia and appetite loss; the lowest sexual-dysfunction and nausea profiles in practical use; a clean drug-interaction sheet; and reliable relief of antipsychotic-induced akathisia at 15 mg.

Where it clearly loses: anyone weight-sensitive, anyone who needs daytime alertness, high-neuroticism anxious depression, TRD augmentation (the "Rocket Fuel" myth), PTSD monotherapy, and OCD.

Mechanism

Mirtazapine is a NaSSA, distinctive because it blocks receptors and does not inhibit monoamine reuptake.

• Alpha-2 adrenergic autoreceptor/heteroreceptor antagonism is the antidepressant core: blocking these presynaptic "brakes" disinhibits release of both norepinephrine and serotonin.
• 5-HT2A and 5-HT2C antagonism: routes the extra serotonin preferentially onto 5-HT1A receptors, and accounts for the low sexual dysfunction, improved slow-wave sleep, and appetite/weight effects.
• 5-HT3 antagonism: the built-in antiemetic effect (why it doesn't cause nausea).
• Potent H1 antihistamine antagonism: the sedation and appetite stimulation. A 15 mg dose already occupies most cortical H1 receptors.

The half-life is ~20–40 hours (label means ~26 h in men and ~37 h in women), which comfortably supports once-daily bedtime dosing. Metabolism is hepatic via CYP2D6, 3A4, and 1A2, with negligible enzyme inhibition.

Everything clinically important about mirtazapine (the sleep, the appetite, the weight, the clean GI and sexual profile) follows directly from this receptor map.

The Bedside Cheat Sheet